Target intelligence / Profile preview

D-Alanyl-D-alanine terminus of bacterial cell wall precursor (D-Ala-D-Ala terminus)

Target
D-Ala-D-Ala terminus
Molecular classification
Other
01

Overview

The D-Alanyl-D-alanine terminus of bacterial cell wall precursors is a dipeptide motif located at the end of the peptidoglycan pentapeptide in the cell wall precursors of most Gram-positive and some Gram-negative bacteria. This motif is essential for cross-linking peptidoglycan strands, a process critical for maintaining bacterial cell wall strength and integrity. Many antibiotics, notably glycopeptides such as vancomycin, exert their activity by binding tightly to the D-Ala-D-Ala terminus, thereby sterically blocking enzymes required for peptidoglycan cross-linking and inhibiting cell wall biosynthesis, which leads to bactericidal activity. Resistance to these drugs often arises through modification of the target terminus, most commonly via substitution of D-Ala-D-Lac in pathogenic bacteria, drastically reducing drug binding and efficacy. The D-Ala-D-Ala motif is not present in mammalian cells, making it a selective and valuable point of therapeutic intervention for bacterial infections.

Other names
D-Ala-D-AlaD-alanyl-D-alanine terminusD-alanyl-D-alanine dipeptidepeptidoglycan pentapeptide terminuscell wall precursor D-Ala-D-Ala
02

Mechanism of action

Drugs like vancomycin bind the D-Ala-D-Ala terminus, sterically blocking peptidoglycan cross-linking enzymes (transglycosylase and transpeptidase) and inhibiting cell wall synthesis, leading to bacterial cell death. β-lactam antibiotics mimic the D-Ala-D-Ala structure and irreversibly acylate the active site serine of transpeptidases, blocking cell wall cross-linking. D-cycloserine inhibits D-alanine racemase and D-Ala-D-Ala ligase, blocking D-Ala-D-Ala synthesis.

03

Biological functions

Cell wall biosynthesisStructural integrity (bacterial cell wall)Precursor in peptidoglycan cross-linking
04

Disease associations

Infection
05

Safety considerations

Target modification (e.g., D-Ala-D-Lac substitution conferring vancomycin resistance)Minimal human safety concerns, as this motif is unique to bacteria, but resistance emergence is a major clinical challenge
06

Interacting drugs

Vancomycin

5 more in the full profile.

Beyond the preview

Go deeper on D-Alanyl-D-alanine terminus of bacterial cell wall precursor (D-Ala-D-Ala terminus).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on D-Alanyl-D-alanine terminus of bacterial cell wall precursor (D-Ala-D-Ala terminus).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call